Dr. Levine on Sequencing of Agents for Ovarian Cancer

Douglas A. Levine, MD
Published Online: Wednesday, Dec 13, 2017



Douglas A. Levine, MD, professor, Department of Obstetrics and Gynecology, director, Division of Gynecologic Oncology, NYU Langone's Perlmutter Cancer Center, discusses the sequencing of agents for patients with ovarian cancer.

Due to precision medicine, sequencing is quite easy, explains Levine. However, it is the interpretation of the sequencing that is more challenging. For newer laboratories, it is important to understand how the validation is done and ensure that the details of the sequence analysis are done well.

It is possible to use the sequencing to determine what mutation is in the tumor, and then refer that patient towards a clinical trial or off-label use of clinical therapies.
 


Douglas A. Levine, MD, professor, Department of Obstetrics and Gynecology, director, Division of Gynecologic Oncology, NYU Langone's Perlmutter Cancer Center, discusses the sequencing of agents for patients with ovarian cancer.

Due to precision medicine, sequencing is quite easy, explains Levine. However, it is the interpretation of the sequencing that is more challenging. For newer laboratories, it is important to understand how the validation is done and ensure that the details of the sequence analysis are done well.

It is possible to use the sequencing to determine what mutation is in the tumor, and then refer that patient towards a clinical trial or off-label use of clinical therapies.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: The Expanding Role of PARP Inhibitors in the Treatment of Ovarian Cancers – Current Strategies and Future DirectionJan 30, 20181.5
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Publication Bottom Border
Border Publication
x